MAZE
Maze Therapeutics, Inc.
36.73
+1.28 (+3.61%)
52w low 21.95
53.65 high
46.6% of range
Financial Analysis
| (USD) | Dec 22 | Dec 23 | Dec 24 | Dec 25 | Trend |
|---|---|---|---|---|---|
| Cash & Equivalents | 99.92M | 29.16M | 196.81M | 189.25M | |
| Current Assets | 106.15M | 34.11M | 201.67M | 349.72M | |
| Net PP&E | 41.23M | 34.98M | 29.92M | 25.16M | |
| Total Assets | 149.96M | 71.50M | 240.54M | 397.13M | |
| Current Liabilities | 20.78M | 16.32M | 20.67M | 22.56M | |
| Total Debt | 32.05M | 49.62M | 26.63M | 23.31M | |
| Total Liabilities | 432.42M | 445.35M | 551.73M | 42.16M | |
| Retained Earnings | -295.27M | -395.69M | -358.43M | -489.55M | |
| Shareholders Equity | -282.46M | -373.85M | -311.18M | 354.97M | |
| Working Capital | 85.37M | 17.79M | 181.00M | 327.16M | |
| Shares Outstanding | 43.78M | 43.78M | 43.78M | 49.34M |
Revenue CAGR
--
Net Income CAGR
--
EPS CAGR
--
FCF CAGR
--
Revenue YoY
-100.0%